OSCR 目前被低估，公允价值高于 41 美元，现价约 30 美元，意味着在增长与成本控制推动下，12-18 个月内有超过 34% 的上行空间。
逐段跳播
最后但同样重要的是Oscar Health，它是在将人工智能整合到运营中以提升效率和业绩方面最顶尖的医疗保健公司之一。它是自2024年以来增长最快的医疗保健公司之一。它实现了超过40%的复合年收入增长率。
管理层预计，从现在到2030年，复合年收入增长率将超过20%。它正在控制成本，而随着收入和净利润的扩张，利润也在改善。
Last but not least, Oscar Health, one of the top healthcare companies in terms of integrating artificial intelligence into its operations to improve efficiency and performance.
It is one of the fastest growing healthcare companies since 2024. It has achieved a compound annual revenue growth rate of over 40%. Management anticipates compound annual revenue growth rates exceeding 20% from now until 2030.
It is controlling costs, and profits are improving as a result of this expansion in revenue and net profit.
我计算出Oscar Health股票的公允价值为每股超过41美元。该股当前市场价格略高于30美元。因此，这一差距为Oscar Health在未来十二到十八个月内创造了超过34%的上涨趋势。
I calculated a fair value for Oscar Health stock at over $41 per share. The current market price of the stock is just over $30. Therefore, this difference creates an upward trend for Oscar Health of more than 34% over the next twelve to eighteen months.
这个频道对 $OSCR 的历次判断
Parkev Tatevosian, CFA 在这只股票上只有这一条判断。